Appendix 4E and 2026 Annual Report

• Revenue from ordinary activities up 15.3% to $42,491,000
• Loss for the year down 142.4% to $(1,408,000)
• Adjusted EBITDA up to $6,487,000
• Net operating cash inflow at $39,000
• Strong growth in European market

Little Green Pharma Ltd's Annual Report for FY2026 shows a 15.3% increase in revenue to $42.5 million, up from $36.8 million in FY2025. The company reported a loss of $1.4 million, down from a profit of $3.3 million in the previous year. Adjusted EBITDA improved to $6.5 million, up from $2.9 million. Net operating cash inflow was $39,000, an improvement from a cash outflow of $917,000 in FY2025. The company's European operations are a key growth driver, with strong demand in Germany and progress in other European markets. The company's vertically integrated model, expanding European footprint, and strong Net Tangible Asset base provide a solid platform for sustainable growth.

Revenue expected to grow by 15.3% in FY2026, Adjusted EBITDA up to $6,487,000

LGP remains well positioned to capitalize on the continued maturation of the medicinal cannabis industry with its vertically integrated model and expanding European footprint.